Teijin Nakashima Doubles Down On Spine And Trauma In Japan
In a deal with Otsuka, Teijin has agreed to acquire KiSCO’s spine and trauma operations, commencing February 2021.
You may also be interested in...
Japan's Teijin is adding a family of bioresorbable, osteosynthetic bone-fixation devices to its modest but growing orthopedics portfolio.
Less than a month after it sold off its reproductive health assets, Invitae has filed for bankruptcy. That will not come as a surprise to anyone following the company.
Freenome, the Roche-backed early cancer detection liquid biopsy developer has raised yet more money, making it one of the best-funded companies in its sub-sector. With trial results due relatively soon, investors are likely hoping this will be the last funding round required before full commercialization.